Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin†
Open Access
- 26 March 2010
- journal article
- viral hepatitis
- Published by Wolters Kluwer Health in Hepatology
- Vol. 51 (4) , 1122-1126
- https://doi.org/10.1002/hep.23444
Abstract
A sustained virologic response (SVR) in patients with chronic hepatitis C receiving pegylated interferon (PEG‐IFN) plus ribavirin is defined as undetectable serum HCV‐RNA at 24 weeks (W+24) posttreatment follow‐up. Viral load outcome in patients with virological relapse (VR) has not been explored. This study evaluated whether the assessment of serum HCV‐RNA 12 weeks (W+12) after the end of treatment was as relevant as W+24 to evaluate SVR in 573 patients who received combination PEG‐IFN and ribavirin and had a virological response at the end of treatment. Serum HCV‐RNA was measured, using a new assay based on transcription‐mediated amplification (TMA) with a lowest detection limit of 5‐10 IU/mL, at W+12 and W+24 after the end of treatment. VR was defined as reappearance of detectable HCV‐RNA at W+24 posttreatment follow‐up. The positive predictive value (PPV) of undetectable serum HCV‐RNA at W+12 was evaluated to identify patients with SVR, and the viral load outcome was measured in relapse patients. At the W+24 posttreatment follow‐up, 408 (71%) patients had an SVR, 181 (71.2%) were treated with PEG‐IFNα‐2a and ribavirin, and 227 (71.1%) were treated with PEG‐IFNα‐2b and ribavirin. At W+12, serum HCV‐RNA was undetectable in 409 patients, and 408 patients were SVR (PPV 99.7%, 95% confidence interval 99.1‐100). In relapse patients, serum HCV‐RNA levels were 5.623 ± 0.748, 4.979 ± 0.870, and 5.216 ± 0.758 log10 IU/mL at baseline, W+12, and W+24, respectively. Conclusion: Our results show that the assessment of serum HCV‐RNA 12 weeks after the end of treatment, using the highly sensitive TMA assay (PPV 99.7%), is as relevant as after 24 weeks to predict SVR and make decisions on the management of treated patients, suggesting a new definition for SVR. (HEPATOLOGY 2010.)Keywords
This publication has 27 references indexed in Scilit:
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapyHepatology, 2009
- Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction–negative samples obtained after treatment of chronic hepatitis CHepatology, 2008
- Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis CJournal of Viral Hepatitis, 2006
- Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapyGut, 2004
- Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA)Journal of Clinical Microbiology, 2004
- Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis CJournal of Hepatology, 2003
- Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirinHepatology, 2002
- A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis CHepatology, 2001
- 10-year follow-up after interferon-α therapy for chronic hepatitis CHepatology, 1998
- Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis CHepatology, 1995